Vascular endothelial growth factor and its soluble receptor in infants with congenital cardiac disease

Area of Science:

• Pediatric Cardiology
• Vascular Biology
• Neonatal Research

Background:

• Major aortopulmonary collaterals are common in cyanotic congenital cardiac disease.
• Vascular endothelial growth factor (VEGF) is crucial for angiogenesis.
• Soluble VEGF receptor-1 (sVEGFR-1) antagonizes VEGF activity.

Purpose of the Study:

• To compare plasma levels of VEGF and sVEGFR-1 in infants with cyanotic versus acyanotic congenital cardiac disease.
• To investigate the role of VEGF and sVEGFR-1 in the context of congenital heart disease and surgical recovery.

Main Methods:

• Study included 30 infants with cyanotic and 27 with acyanotic congenital cardiac disease.
• Central venous plasma samples were collected pre-surgery and at 24 and 96 hours post-surgery.
• Plasma levels of VEGF and sVEGFR-1 were quantified using established assays.

Main Results:

• No significant difference in plasma VEGF levels was observed between cyanotic and acyanotic infants.
• Plasma sVEGFR-1 levels showed a trend towards being higher in cyanotic infants compared to acyanotic infants.
• Post-operative changes in VEGF and sVEGFR-1 levels were not detailed in the abstract.

Conclusions:

• Plasma VEGF and sVEGFR-1 levels do not significantly differ between infants with cyanotic and acyanotic congenital cardiac disease.
• The findings suggest that angiogenesis regulation via VEGF and sVEGFR-1 may not be a primary differentiator in these patient groups.
• Further research is needed to fully elucidate the role of these factors in congenital heart disease pathophysiology.